Key result
FFR-based deferral of revascularization in chronic coronary syndrome had an 11.6% 5-year target vessel failure rate, similar between FFR 0.75-0.80 and 0.81-0.85.
Why the study?
Little large-scale data was available regarding clinical outcomes beyond 3 years after fractional flow reserve–based deferral of revascularization in routine clinical practice.
Cohort (n=1,263)
Yes
FFR-based deferral of revascularization in patients with chronic coronary syndrome demonstrates long-term safety with a 5-year target vessel failure rate of 11.6% and very low rates of hard clinical events.
Answers are grounded in this paper and cite their sources.
Supports safety of FFR deferral in chronic coronary syndrome; leaves open need for randomized confirmation.
Background: Little large-scale data is available about the long-term (beyond 3 years) clinical outcomes after fractional flow reserve (FFR)–based deferral of revascularization in clinical practice. We sought to assess the 5-year outcomes after deferral of revascularization based on FFR. Methods: The J-CONFIRM registry (Long-Term Outcomes of Japanese Patients With Deferral of Coronary Intervention Based on Fractional Flow Reserve in Multicenter Registry) prospectively enrolled 1263 patients with 1447 lesions in whom revascularization was deferred based on FFR from 28 Japanese centers. The primary study end point was the cumulative 5-year incidence of target vessel failure (TVF), including cardiac death, target vessel–related myocardial infarction, and clinically driven target vessel revascularization. Results: Five-year follow-up was completed in 92.2% of patients. The 5-year TVF rate was 11.6% in deferred lesions, mainly driven by clinically driven target vessel revascularization (9.8%). Cardiac death and target vessel–related myocardial infarction were 1.9% and 0.95%, respectively. Cumulative 5-year incidence of TVF was similar between the FFR 0.75 to 0.80 and 0.81 to 0.85 groups even after adjustment for baseline characteristics (12.2% versus 13.0%, inverse probability–weighted hazard ratio, 0.86 [95% CI, 0.46–1.60]; P =0.63). Compared with the almost normal FFR (0.86–1.00) group, the significant (<0.75) and borderline (0.75–0.85) FFR groups showed a higher incidence of TVF at 5 years (29.9% versus 12.8% versus 8.6%, P <0.001). Independent predictors of the 5-year TVF were hemodialysis, FFR value, left main coronary artery lesion, prior percutaneous coronary intervention, and male sex. Conclusions: The 5-year TVF rate was 11.6% in deferred lesions, mainly driven by clinically driven target vessel revascularization. Notably, cardiac death and target vessel–related myocardial infarction rarely occurred during the follow-up. Our findings highlight the long-term safety of FFR-based deferral of revascularization in patients with chronic coronary syndrome. Registration: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000014473.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Chronic coronary syndrome (n=1,263). Fractional flow reserve (FFR) 0.75 to 0.80 vs. FFR 0.81 to 0.85 was evaluated on Cumulative 5-year incidence of target vessel failure (TVF), including cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization (HR 0.86, 95% CI 0.46-1.60, p=0.63). FFR-based deferral of revascularization in chronic coronary syndrome had an 11.6% 5-year target vessel failure rate, similar between FFR 0.75-0.80 and 0.81-0.85.
Synapse has enriched 10 related papers. Consider them for comparative context: